196 related articles for article (PubMed ID: 25361812)
1. Preclinical efficacy of MEK inhibition in Nras-mutant AML.
Burgess MR; Hwang E; Firestone AJ; Huang T; Xu J; Zuber J; Bohin N; Wen T; Kogan SC; Haigis KM; Sampath D; Lowe S; Shannon K; Li Q
Blood; 2014 Dec; 124(26):3947-55. PubMed ID: 25361812
[TBL] [Abstract][Full Text] [Related]
2. RAB27B controls palmitoylation-dependent NRAS trafficking and signaling in myeloid leukemia.
Ren JG; Xing B; Lv K; O'Keefe RA; Wu M; Wang R; Bauer KM; Ghazaryan A; Burslem GM; Zhang J; O'Connell RM; Pillai V; Hexner EO; Philips MR; Tong W
J Clin Invest; 2023 Jun; 133(12):. PubMed ID: 37317963
[TBL] [Abstract][Full Text] [Related]
3. Mechanistic and Preclinical Insights from Mouse Models of Hematologic Cancer Characterized by Hyperactive Ras.
Wandler A; Shannon K
Cold Spring Harb Perspect Med; 2018 Apr; 8(4):. PubMed ID: 28778967
[No Abstract] [Full Text] [Related]
4. Mechanism of co-operation of mutant
Winer H; Li W; Rodrigues G; Gower T; Meyer TJ; Hixon J; Durum SK
Haematologica; 2023 Nov; 109(6):1726-40. PubMed ID: 38031763
[TBL] [Abstract][Full Text] [Related]
5. Primary myeloid sarcoma in an infant with an NRAS mutation.
Kamat A; Opipari V; Habiger C; Jasty R; Mody R; Sedig L
Pediatr Blood Cancer; 2024 Jun; 71(6):e30946. PubMed ID: 38462746
[No Abstract] [Full Text] [Related]
6. Cooperative loss of RAS feedback regulation drives myeloid leukemogenesis.
Zhao Z; Chen CC; Rillahan CD; Shen R; Kitzing T; McNerney ME; Diaz-Flores E; Zuber J; Shannon K; Le Beau MM; Spector MS; Kogan SC; Lowe SW
Nat Genet; 2015 May; 47(5):539-43. PubMed ID: 25822087
[TBL] [Abstract][Full Text] [Related]
7. KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer.
Burgess MR; Hwang E; Mroue R; Bielski CM; Wandler AM; Huang BJ; Firestone AJ; Young A; Lacap JA; Crocker L; Asthana S; Davis EM; Xu J; Akagi K; Le Beau MM; Li Q; Haley B; Stokoe D; Sampath D; Taylor BS; Evangelista M; Shannon K
Cell; 2017 Feb; 168(5):817-829.e15. PubMed ID: 28215705
[TBL] [Abstract][Full Text] [Related]
8. Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies.
Borthakur G; Popplewell L; Boyiadzis M; Foran J; Platzbecker U; Vey N; Walter RB; Olin R; Raza A; Giagounidis A; Al-Kali A; Jabbour E; Kadia T; Garcia-Manero G; Bauman JW; Wu Y; Liu Y; Schramek D; Cox DS; Wissel P; Kantarjian H
Cancer; 2016 Jun; 122(12):1871-9. PubMed ID: 26990290
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic NRAS Primes Primary Acute Myeloid Leukemia Cells for Differentiation.
Brendel C; Teichler S; Millahn A; Stiewe T; Krause M; Stabla K; Ross P; Huynh M; Illmer T; Mernberger M; Barckhausen C; Neubauer A
PLoS One; 2015; 10(4):e0123181. PubMed ID: 25901794
[TBL] [Abstract][Full Text] [Related]
10. Wild-type KRAS inhibits oncogenic KRAS-induced T-ALL in mice.
Staffas A; Karlsson C; Persson M; Palmqvist L; Bergo MO
Leukemia; 2015 May; 29(5):1032-40. PubMed ID: 25371176
[TBL] [Abstract][Full Text] [Related]
11. Improved overall survival in melanoma with combined dabrafenib and trametinib.
Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
[TBL] [Abstract][Full Text] [Related]
12. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer.
Westcott PM; Halliwill KD; To MD; Rashid M; Rust AG; Keane TM; Delrosario R; Jen KY; Gurley KE; Kemp CJ; Fredlund E; Quigley DA; Adams DJ; Balmain A
Nature; 2015 Jan; 517(7535):489-92. PubMed ID: 25363767
[TBL] [Abstract][Full Text] [Related]
13. The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells.
Wada M; Horinaka M; Yamazaki T; Katoh N; Sakai T
PLoS One; 2014; 9(11):e113217. PubMed ID: 25422890
[TBL] [Abstract][Full Text] [Related]
14. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.
Lindsley RC; Mar BG; Mazzola E; Grauman PV; Shareef S; Allen SL; Pigneux A; Wetzler M; Stuart RK; Erba HP; Damon LE; Powell BL; Lindeman N; Steensma DP; Wadleigh M; DeAngelo DJ; Neuberg D; Stone RM; Ebert BL
Blood; 2015 Feb; 125(9):1367-76. PubMed ID: 25550361
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
Tolcher AW; Patnaik A; Papadopoulos KP; Rasco DW; Becerra CR; Allred AJ; Orford K; Aktan G; Ferron-Brady G; Ibrahim N; Gauvin J; Motwani M; Cornfeld M
Cancer Chemother Pharmacol; 2015 Jan; 75(1):183-9. PubMed ID: 25417902
[TBL] [Abstract][Full Text] [Related]
16. B-Raf inhibitors induce epithelial differentiation in BRAF-mutant colorectal cancer cells.
Herr R; Köhler M; Andrlová H; Weinberg F; Möller Y; Halbach S; Lutz L; Mastroianni J; Klose M; Bittermann N; Kowar S; Zeiser R; Olayioye MA; Lassmann S; Busch H; Boerries M; Brummer T
Cancer Res; 2015 Jan; 75(1):216-29. PubMed ID: 25381152
[TBL] [Abstract][Full Text] [Related]
17. Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer.
Junttila MR; Devasthali V; Cheng JH; Castillo J; Metcalfe C; Clermont AC; Otter DD; Chan E; Bou-Reslan H; Cao T; Forrest W; Nannini MA; French D; Carano R; Merchant M; Hoeflich KP; Singh M
Mol Cancer Ther; 2015 Jan; 14(1):40-7. PubMed ID: 25376606
[TBL] [Abstract][Full Text] [Related]
18. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.
Lin L; Sabnis AJ; Chan E; Olivas V; Cade L; Pazarentzos E; Asthana S; Neel D; Yan JJ; Lu X; Pham L; Wang MM; Karachaliou N; Cao MG; Manzano JL; Ramirez JL; Torres JM; Buttitta F; Rudin CM; Collisson EA; Algazi A; Robinson E; Osman I; Muñoz-Couselo E; Cortes J; Frederick DT; Cooper ZA; McMahon M; Marchetti A; Rosell R; Flaherty KT; Wargo JA; Bivona TG
Nat Genet; 2015 Mar; 47(3):250-6. PubMed ID: 25665005
[TBL] [Abstract][Full Text] [Related]
19. Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations.
Ohgami RS; Ma L; Merker JD; Gotlib JR; Schrijver I; Zehnder JL; Arber DA
Mod Pathol; 2015 May; 28(5):706-14. PubMed ID: 25412851
[TBL] [Abstract][Full Text] [Related]
20. Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor.
Juric D; Castel P; Griffith M; Griffith OL; Won HH; Ellis H; Ebbesen SH; Ainscough BJ; Ramu A; Iyer G; Shah RH; Huynh T; Mino-Kenudson M; Sgroi D; Isakoff S; Thabet A; Elamine L; Solit DB; Lowe SW; Quadt C; Peters M; Derti A; Schegel R; Huang A; Mardis ER; Berger MF; Baselga J; Scaltriti M
Nature; 2015 Feb; 518(7538):240-4. PubMed ID: 25409150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
